CliffBio
small molecule

RENVELA

SEVELAMER CARBONATE

Loss of exclusivity—loss of exclusivity
CompanySanofi Genzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameRENVELA
Active ingredientSEVELAMER CARBONATE
Strength800MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2007
Marketing statusDISCN

More from Sanofi Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.